SLC5A2 and chronic kidney disease: A reference clinical study involving the therapeutic effects of SGLT2 is EMPA-KIDNEY, which confirmed the cardiorenal protective action of SGLT2 inhibitors, supporting their use in both the primary prevention and treatment of CKD [201].